| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9184314 | Seminars in Thoracic and Cardiovascular Surgery | 2005 | 4 Pages |
Abstract
The survival after complete resection for non-small cell lung cancer (NSCLC) is unsatisfactory. Until recently, the use of adjuvant therapy after resection for early stage disease has not been proven to improve survival. However, the efficacy of adjuvant therapy has been demonstrated in phase III prospective randomized trials. The appropriate use of adjuvant therapy, including biologic therapy, is currently under investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Thomas A. MD,